A Phase 3 interventional study of Placebo and Relamorelin in Gastroparesis and Diabetes Mellitus, sponsored by Allergan. Terminated at 337 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-22.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.
Among the 184 studies in Gastroparesis with a site in United States, this one is the 3rd largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2018, is one of 12 in phase 3, and was the 90th registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:
Evan (Huiliang) Wang · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–65
Viral N. Shah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 42 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 467 is above the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 36 across the 136 interventional studies, 108 across the 39 observational. Of the 124 that completed or were terminated, 63 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 184 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 7 studies filed under Gastroparesis — fewer than ten, so there is no comparison to draw.
14 of the studies in Gastroparesis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06046833Samita GargContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes | 2026-12 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 184 studies in Gastroparesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo for 6 additional weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo-matching relamorelin injected subcutaneously twice daily for up to 40 weeks.
Drug: Placebo
Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 40 weeks.
Drug: Relamorelin
Participants who received placebo-matching relamorelin injected subcutaneously twice daily for 40 weeks, followed by relamorelin 10 μg injected twice daily for up to 6 weeks in the Randomized Withdrawal (RW) Period.
Drug: Placebo · Drug: Relamorelin
Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by relamorelin injected twice daily for up to 6 weeks in the RW Period.
Drug: Relamorelin
Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by placebo-matching relamorelin injected twice daily for up to 6 weeks in the RW Period.
Drug: Placebo · Drug: Relamorelin
Placebo injected twice daily
Relamorelin 10 μg injected twice daily
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) of the Treatment Period
Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to Week 12 of this study
Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period.
Time frame: Week 6 to Week 12
Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
A Nausea Responder was defined as a participant with improvement (decrease) of at least 2-points in the weekly symptom scores for nausea at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Nausea was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0=no nausea to 10=worst possible nausea. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)
Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
An Abdominal Pain Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for abdominal pain at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Abdominal pain was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0=no abdominal pain to 10=the worst possible abdominal pain and was recorded in an e-diary. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)
Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
A Bloating Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for bloating at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Bloating was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0=no bloating and 10=the worst possible bloating and was recorded in the e-diary. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)
Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
A Postprandial Fullness Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for Postprandial Fullness at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Postprandial Fullness was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0=no feeling of fullness until finishing a meal (best) to 10=feeling full after only a few bites (worst). Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 6 to Week 12)
Change From Baseline to Week 40 in the Average Weekly DGSSS of the Treatment Period
Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an e-diary. The DGSSS was derived as the sum of the weekly averages (Week 37 to Week 40) of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous studies.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 37 to Week 40)
Percentage of Participants Meeting the Vomiting Responder Criterion at Week 40 of the Treatment Period
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during the last 4 weeks of the 40-week Treatment Period.
Time frame: Week 37 to Week 40
Change From Baseline to Week 40 in the Average Weekly Number of Vomiting Episodes of the Treatment Period
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. The average weekly number of vomiting episodes were derived as the average of the weekly number of vomiting episodes in the last 4 weeks of the 40-week Treatment Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 37 to Week 40)
Change From Baseline to Week 46 in the Average Weekly DGSSS of the Randomized-Withdrawal Period
Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an e-diary. The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). Average weekly scores are derived as the average of the weekly scores from the 6 weeks of the RW Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 41 to Week 46)
Change From Baseline to Week 46 in the Average Weekly Number of Vomiting Episodes of the Randomized-Withdrawal Period
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. Average weekly number of vomiting episodes are derived as the average of the weekly number of vomiting episodes from the six weeks of the RW Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
Time frame: Baseline (14-day Run-in Period of the previous relamorelin study RLM-MD-01 or RLM-MD-02) to (Week 41 to Week 46)
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.
Time frame: First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 50 weeks)
Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
Clinical Laboratory values included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Time frame: Up to 46 weeks
Number of Participants With Clinically Meaningful Trends for Vital Signs
Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the results were clinically significant.
Time frame: Up to 46 weeks
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results
A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.
Time frame: Up to 46 weeks
Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c)
Time frame: Up to 46 weeks
Number of Participants With Anti-relamorelin Antibody Testing Results
A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay.
Time frame: Up to 46 weeks
| Milestone | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|---|---|
| Started | 236 | 231 | 0 | 0 | 0 |
| Safety population | 235 | 231 | 0 | 0 | 0 |
| Completed | 92 | 105 | 0 | 0 | 0 |
| Not completed | 144 | 126 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 6 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 22 | 16 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 6 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 3 | 4 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Study terminated by the sponsor | 101 | 89 | 0 | 0 | 0 |
| Withdrew: Site terminated by the sponsor | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 3 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|---|---|
| Started | 0 | 0 | 91 | 59 | 43 |
| Completed | 0 | 0 | 85 | 54 | 38 |
| Not completed | 0 | 0 | 6 | 5 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Study terminated by the sponsor | 0 | 0 | 6 | 3 | 3 |
Participants assessed the severity of diabetic gastroparesis symptoms daily using the Diabetic Gastroparesis Symptom Severity Diary (DGSSD), recorded in an electronic diary (e-diary). The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
| score on a scale | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg |
|---|---|---|
| Baseline | 24.9 ± 5.65 | 24.8 ± 6.28 |
| Change from Baseline to Week 12 | -11.9 ± 9.43 | -11.2 ± 9.00 |
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period.
| percentage of participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | 29.4 | 21.4 |
A Nausea Responder was defined as a participant with improvement (decrease) of at least 2-points in the weekly symptom scores for nausea at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Nausea was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0=no nausea to 10=worst possible nausea. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
| percentage of participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Nausea Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | 46.0 | 43.2 |
An Abdominal Pain Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for abdominal pain at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Abdominal pain was one of the items of the DGSSD assessed daily and recorded in the e-diary by the participant using an 11-point ordinal scale where: 0=no abdominal pain to 10=the worst possible abdominal pain and was recorded in an e-diary. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
| percentage of participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Abdominal Pain Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | 40.4 | 39.7 |
A Bloating Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for bloating at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Bloating was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0=no bloating and 10=the worst possible bloating and was recorded in the e-diary. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
| percentage of participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Bloating Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | 38.3 | 38.4 |
A Postprandial Fullness Responder was defined as a participant with an improvement (decrease) of at least 2-points in the weekly symptom scores for Postprandial Fullness at each of the last 6 weeks of the first 12-weeks of the 40-week Treatment Period. Postprandial Fullness was one of the items of the DGSSD assessed daily and recorded by the participant in the e-diary using an 11-point ordinal scale where: 0=no feeling of fullness until finishing a meal (best) to 10=feeling full after only a few bites (worst). Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
| percentage of participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Postprandial Fullness Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period | 36.6 | 36.2 |
Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an e-diary. The DGSSS was derived as the sum of the weekly averages (Week 37 to Week 40) of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period of the previous studies.
| score on a scale | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg |
|---|---|---|
| Baseline | 24.9 ± 5.65 | 24.8 ± 6.28 |
| Change from Baseline to Week 40 | -13.3 ± 10.22 | -12.3 ± 9.20 |
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. A Vomiting Responder was defined as a participant with zero weekly vomiting episodes during the last 4 weeks of the 40-week Treatment Period.
| percentage of participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg |
|---|---|---|
| Percentage of Participants Meeting the Vomiting Responder Criterion at Week 40 of the Treatment Period | 19.1 | 18.8 |
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. The average weekly number of vomiting episodes were derived as the average of the weekly number of vomiting episodes in the last 4 weeks of the 40-week Treatment Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
| vomiting episodes per week | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg |
|---|---|---|
| Baseline | 6.8 ± 11.09 | 7.3 ± 11.52 |
| Change from Baseline to Week 40 | -1.8 ± 17.51 | -5.4 ± 11.87 |
Participants assessed the severity of diabetic gastroparesis symptoms daily using the DGSSD, recorded in an e-diary. The DGSSS was derived as the sum of the weekly averages of the 4 DGSSD items: nausea, abdominal pain, postprandial fullness and bloating. Each symptom was scored using an 11-point ordinal scale where: 0=no or not at all uncomfortable to 10=worst possible or most uncomfortable for a total possible DGSSS of 0 (best) to 40 (worst). Average weekly scores are derived as the average of the weekly scores from the 6 weeks of the RW Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
| score on a scale | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|
| Baseline | 25.7 ± 5.65 | 25.7 ± 6.25 | 24.4 ± 5.47 |
| Change from Baseline to Week 46 | -13.4 ± 10.45 | -12.5 ± 9.71 | -12.5 ± 9.35 |
The number of vomiting episodes in the previous 24 hours were assessed daily by the participant using the DGSSD and were recorded in the e-diary. Average weekly number of vomiting episodes are derived as the average of the weekly number of vomiting episodes from the six weeks of the RW Period. A negative change from Baseline indicates improvement. Baseline was defined as the average of the 2 weekly DGSSS from the run-in period in the previous studies.
| vomiting episodes per week | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|
| Baseline | 6.1 ± 7.01 | 9.9 ± 11.92 | 4.2 ± 4.73 |
| Change from Baseline to Week 46 | -1.8 ± 18.40 | -7.3 ± 10.23 | -1.8 ± 6.12 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE is an AE that begins or worsens after receiving study drug.
| Participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|---|---|
| Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE) | 129 | 131 | 18 | 12 | 8 |
Clinical Laboratory values included Hematology, Chemistry and Urinalysis tests. The investigator determined if the results were clinically significant. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
| Participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|---|---|
| Eosinophils Absolute Cell Count [10^9/liter(L)]: >3×Upper Limit of Normal Value (ULN) | 2 | 1 | 0 | 1 | 1 |
| Hematocrit (RATIO): >1.1×ULN | 1 | 2 | 2 | 1 | 0 |
| Hematocrit (RATIO): <0.9×Lower Limit of Normal Value (LLN) | 7 | 7 | 4 | 0 | 2 |
| Hemoglobin [grams (g)/L]: <0.9×LLN | 13 | 14 | 5 | 1 | 4 |
| Lymphocytes Absolute Cell Count (10^9/L): <0.8×LLN | 1 | 4 | 0 | 0 | 0 |
| Mean Corpuscular Volume [femtoliter (fL)]: >1.1×ULN | 2 | 3 | 1 | 0 | 0 |
| Mean Corpuscular Volume (fL): <0.9×LLN | 4 | 0 | 1 | 0 | 0 |
| Neutrophils Absolute Cell Count (10^9/L): >1.5×ULN | 0 | 2 | 2 | 0 | 0 |
| Neutrophils Absolute Cell Count (10^9/L): <0.8×LLN | 6 | 4 | 2 | 0 | 0 |
| Platelet Count (Thrombocytes) (10^9/L): >1.5×ULN | 0 | 1 | 0 | 0 | 0 |
| Platelet Count (Thrombocytes) (10^9/L): <0.5×LLN | 1 | 0 | 0 | 0 | 0 |
| Red Blood Cell Count (10^12/L): >1.1×ULN | 1 | 0 | 0 | 0 | 0 |
| Red Blood Cell Count (10^12/L): <0.9×LLN | 4 | 8 | 4 | 1 | 0 |
| White Blood Cell Count (10^9/L): <0.7×LLN | 2 | 0 | 0 | 0 | 0 |
| Alanine Aminotransferase [Serum Glutamic Pyruvic Transaminase (SGPT)] [unit(U)/L]: >=3×ULN | 2 | 2 | 0 | 2 | 1 |
| Albumin (g/L): <0.9×LLN | 1 | 1 | 1 | 0 | 1 |
| Alkaline Phosphatase (U/L): >=3×ULN | 0 | 3 | 0 | 0 | 0 |
| Aspartate Aminotransferase [Serum Glutamic Oxaloacetic Transaminase (SGOT)] (U/L): >=3×ULN | 3 | 2 | 0 | 0 | 0 |
| Bicarbonate (HCO3) [millimoles (mmol)/L]: >1.1×ULN | 3 | 2 | 1 | 1 | 0 |
| Bicarbonate (HCO3) (mmol)/L: >0.9×LLN | 6 | 9 | 2 | 4 | 1 |
| Bilirubin, Total [micromoles(μmol)/L]: >1.5×ULN | 1 | 0 | 0 | 0 | 0 |
| Blood Urea Nitrogen (mmol/L): >1.2×ULN | 29 | 20 | 8 | 4 | 4 |
| Calcium (mmol/L): >1.1×ULN | 1 | 0 | 1 | 0 | 0 |
| Calcium (mmol/L): <0.9×LLN | 1 | 0 | 0 | 0 | 1 |
| Chloride (mmol/L): <0.9×LLN | 2 | 1 | 1 | 0 | 1 |
| Cholesterol, Total, Fasting (mmol/L): >1.6×ULN | 4 | 1 | 0 | 1 | 0 |
| Creatinine (μmol/L): >1.3×ULN | 22 | 16 | 5 | 2 | 3 |
| Glucose-Chemistry, Fasting (mmol/L): >2.5×ULN | 41 | 33 | 9 | 9 | 4 |
| Glucose-Chemistry, Fasting (mmol/L): <0.9×LLN | 14 | 9 | 4 | 2 | 2 |
| Glycohemoglobin A1C: Increase of >=0.5% | 134 | 138 | 62 | 26 | 28 |
| Glycohemoglobin A1C: Increase of >=1% | 134 | 138 | 62 | 26 | 28 |
| Phosphorus (mmol/L): >1.1×ULN | 10 | 12 | 4 | 4 | 4 |
| Phosphorus (mmol/L): <0.9×LLN | 4 | 3 | 0 | 0 | 0 |
| Potassium (mmol/L): <0.9×LLN | 0 | 0 | 2 | 0 | 0 |
| Protein, Total (g/L): >1.1×ULN | 0 | 1 | 0 | 0 | 0 |
| Protein, Total (g/L): <0.9×LLN | 0 | 1 | 0 | 0 | 1 |
| Triglycerides, Fasting (mmol/L): >=3×ULN | 9 | 11 | 4 | 4 | 2 |
| Uric Acid (Urate) (μmol/L): >1.1×ULN | 31 | 31 | 5 | 3 | 1 |
| Uric Acid (Urate) (μmol/L): <0.9×LLN | 3 | 4 | 1 | 0 | 0 |
Vital Signs included assessments of heart rate, respiratory rate, systolic and diastolic blood pressure, and body temperature. The investigator determined if the results were clinically significant.
| Participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Trends for Vital Signs | 0 | 0 | 0 | 0 | 0 |
A standard 12-lead ECG was performed. The investigator determined if the abnormal results were clinically significant.
| Participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results | 3 | 2 | 0 | 0 | 0 |
| Participants | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|---|---|
| Number of Participants With a ≥1% Increase in Glycosylated Hemoglobin A1c (HBA1c) | 134 | 138 | 62 | 26 | 28 |
A blood sample was collected that was sent to a laboratory for an anti-relamorelin antibody screening test. A positive screening test was confirmed by an immunodepletion assay.
No measurements were reported for this outcome.
Collected over First dose of study drug to within 30 days of the last dose of study drug (Up to approximately 50 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period: Placebo | 3/236 (1.3%) | 24/235 (10.2%) | 18/235 (7.7%) |
| Treatment Period: Relamorelin 10 μg | 2/231 (0.9%) | 20/231 (8.7%) | 27/231 (11.7%) |
| Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | 0/91 (0%) | 3/91 (3.3%) | 0/91 (0%) |
| Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | 0/59 (0%) | 2/59 (3.4%) | 0/59 (0%) |
| Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo | 0/43 (0%) | 1/43 (2.3%) | 0/43 (0%) |
| Event | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|---|---|
| Rib fractureInjury, poisoning and procedural complications | 0/235 | 0/231 | 0/91 | 0/59 | 1/43 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/235 | 1/231 | 0/91 | 0/59 | 1/43 |
| SyncopeNervous system disorders | 1/235 | 0/231 | 0/91 | 1/59 | 1/43 |
| Hypertensive encephalopathyNervous system disorders | 0/235 | 0/231 | 0/91 | 0/59 | 1/43 |
| Acute kidney injuryRenal and urinary disorders | 4/235 | 3/231 | 0/91 | 0/59 | 1/43 |
| Accelerated hypertensionVascular disorders | 0/235 | 0/231 | 0/91 | 0/59 | 1/43 |
| Myocardial infarctionCardiac disorders | 0/235 | 0/231 | 0/91 | 1/59 | 0/43 |
| Postinfarction anginaCardiac disorders | 0/235 | 0/231 | 0/91 | 1/59 | 0/43 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 2/235 | 3/231 | 0/91 | 0/59 | 0/43 |
| Coronary artery diseaseCardiac disorders | 3/235 | 1/231 | 0/91 | 0/59 | 0/43 |
| Event | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Randomized Withdrawal Period: Placebo Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Relamorelin 10 μg | Randomized Withdrawal Period: Relamorelin 10 μg Then Placebo |
|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 13/235 | 16/231 | 0/91 | 0/59 | 0/43 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/235 | 12/231 | 0/91 | 0/59 | 0/43 |
ITT Population included all participants who entered the 40-week treatment period.
| Age, Continuous(years) | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Total |
|---|---|---|---|
| Mean | 55.5 ± 11.11 | 56.2 ± 11.51 | 55.9 ± 11.30 |
| Sex: Female, Male(Participants) | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Total |
|---|---|---|---|
| Female | 162 | 166 | 328 |
| Male | 74 | 65 | 139 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Total |
|---|---|---|---|
| Hispanic or Latino | 83 | 82 | 165 |
| Not Hispanic or Latino | 153 | 149 | 302 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Period: Placebo | Treatment Period: Relamorelin 10 μg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 8 | 11 |
| Asian | 21 | 18 | 39 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 37 | 21 | 58 |
| White | 175 | 183 | 358 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 337 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Oct 2020, 33 months.
Results were first posted in Dec 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relamorelin